Company: AZN
Filing Date: 2025-10-07
Form Type: 6-K
Source: 0001654954-25-011529
Chunk: 2

Company: ASTRAZENECA PLC
Filing Date: 2025-10-07
Form: 6-K
Chunk 2
---
. 11,12 Baxdrostat is currently being investigated as a monotherapy for hypertension 13-15 and primary aldosteronism, 16 and in combination with dapagliflozin for chronic kidney disease 17,18 and the prevention of heart failure in high-risk patients. 19

#### Notes

#### Hard-to-control hypertension
Hypertension is a medical condition characterised by consistently high blood pressure levels, affecting an estimated 1.4 billion people worldwide. 4,20,21 Over time, this can damage blood vessels and vital organs, increasing the risk of serious health problems such as heart attack, stroke, heart failure and kidney disease. 20,21 An observational study of nearly 60,000 patients studied over a median of 9.7 years showed that a 9.5 mmHg increase in SBP was associated with a 30% increase in risk of all-cause mortality and 41% increase in risk of cardiovascular death. 10 Studies have shown that increased night-time blood pressure is associated with higher cardiovascular risk, 7,10 and patients with hypertension have a higher risk of cardiovascular events like heart attack, stroke and death around the time of their morning blood pressure surge. 1,2

Hard-to-control (uncontrolled and resistant) hypertension remains a major public health challenge. 22 Despite lifestyle changes and the use of multiple medications, approximately 50% of patients in the US who are being treated for hypertension still do not have their blood pressure under control. 5 Uncontrolled hypertension refers to persistently elevated blood pressure despite the use of two or more medications, while rHTN, a more severe form, remains elevated despite treatment with three or more medications. 5,20

A key contributor to hard-to-control hypertension is aldosterone, a hormone that raises blood pressure by promoting sodium and water retention. 23,24 Elevated aldosterone levels, along with factors such as obesity, high salt intake, and various genetic or secondary conditions, 25 are strongly associated with poor blood pressure control. When left untreated, hypertension significantly increases the risk of cardiovascular and kidney-related complications. 20,21

#### Bax24 trial
The Phase III Bax24 trial 15 is a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2mg baxdrostat versus placebo, administered once a day (QD) orally, on the reduction of ambulatory SBP in participants